Pulling SEC filings + quote and writing the call…
KURA
Kura Oncology, Inc.
Next earnings Aug 5, 2026 · consensus $-0.90 EPS, $21.3M rev
Last earnings +1.8% on 2026-05-12
$10.12
▲ +1.91%$9.93▲ +53.00%
over 1Y
L $5.54EODHDH $12.14
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+1.9%
1W+12.1%
1M+10.8%
3M+17.8%
YTD-3.9%
1Y+53.0%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 22 analysts
Buy
Revenue grew 25.2% YoY; but unprofitable (net margin -412.9%).
Kura Oncology, Inc. shows $67.5M in FY2025 revenue (+25.2% YoY), a -412.9% net margin, and -160.0% ROE.
Sources: SEC EDGAR (CIK 0001422143, latest 10-Q filed 2026-05-12) · EODHD · as of 6/22/2026, 1:52:31 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.